Identification of a subgroup of Dprague-Dawley rats highly sensitive to drug-induced renal toxicity

1986 ◽  
Vol 7 (1) ◽  
pp. 126-131 ◽  
Author(s):  
J EDMONDRIVIERE
1986 ◽  
Vol 7 (1) ◽  
pp. 126-131
Author(s):  
J. EDMOND RIVIERE ◽  
LYNN P. Dix ◽  
MICHAEL P. CARVER ◽  
DONITA L. FRAZIER

2008 ◽  
Vol 45 (6) ◽  
pp. 945-948 ◽  
Author(s):  
R. E. Guzman ◽  
K. Datta ◽  
N. K. Khan

We have observed a renal toxicity consistent with an obstructive protein cast nephropathy in cynomolgus macaques but not in other species treated with different therapeutic candidates having a common carboxylic acid moiety, suggesting a species-specific sensitivity. Here, we present renal toxicity findings consistent with a protein cast nephropathy in a 2–week safety study in cynomolgus monkeys. Light microscopic changes consisted of intratubular cast formation, tubular dilatation, interstitial inflammation, and expansion of the medullary interstitium. Tubular cast material was identified as Tamm-Horsfall protein (THP) and, on ultrastructure, crystalloid material was present in vacuoles of tubular epithelium. It is hypothesized that microcrystal formation in the urinary tubular spaces induces aggregation of THP protein and cast formation in monkeys. Drug-induced obstructive nephropathy is not identified as a major problem in humans; thus, the clinical relevance of the above findings in monkeys is not clear.


Kidney ◽  
2013 ◽  
pp. 103-120
Author(s):  
Rajiv Govindaraj ◽  
Prasannavenkatesh Durai ◽  
Sangdun Choi

2018 ◽  
Vol 46 (8) ◽  
pp. 1002-1005
Author(s):  
Mary B. Nabity ◽  
Joseph W. Polli ◽  
Vishal Vaidya ◽  
Andrzej Krolewski ◽  
Warren E. Glaab

A scientific session entitled “New Frontiers: Approaches to Understand the Mechanistic Basis of Renal Toxicity” focused on novel biomarkers to monitor kidney injury both preclinically and clinically, as well as providing mechanistic insight of the induced injury. Further, the role and impact of kidney membrane transporters in drug-induced kidney toxicity provided additional considerations when understanding kidney injury and the complex role of drug transporters in either sensitivity or resistance to drug-induced injury. The onset of nephropathy in diabetic patients was also presented, focusing on the quest to discover novel biomarkers that would differentiate diabetic populations more susceptible to nephropathy and renal failure. The session highlighted exciting new research areas and novel biomarkers that will enhance our understanding of kidney injury and provide tools for ensuring patient safety clinically.


Talanta ◽  
2019 ◽  
Vol 203 ◽  
pp. 1-8 ◽  
Author(s):  
Yi−Jun Gong ◽  
Zhen−Zhen Kong ◽  
Ming-Lu Zhang ◽  
Meng−Ke Lv ◽  
Guisheng Zhang

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
H.W. Hoek ◽  
P.N. van Harten

Patients with movement disorders do not always complain about their ‘troubles with muscles’ spontaneously, and sometimes, often out of shame, they try to hide their involuntary movements. E.g. a hand tremor can be temporarily suppressed by pushing the hand against the body or sitting on it. To reveal these movement disorders, a systematic investigation of the patient is required. This investigation consists of a (hetero) anamnesis and a physical examination. The anamnesis demands knowledge of sensitive questions such as: ‘Do you notice any movements that are not under your control? Do you feel restless: an inability to keep the legs still? Do you tremble, are you slower than usual?’ Next, a physical examination is required. The investigator lets the patient execute several movements such as stretching the arms, opening the mouth and walking.In this workshop you will learn and practice this highly sensitive examination. In clinical practice this investigation takes less than 5 minutes and will reveal all drug induced movement disorders.


2012 ◽  
Vol 84 (17) ◽  
pp. 7350-7358 ◽  
Author(s):  
Lingao Ruan ◽  
Zhancheng Xu ◽  
Tao Lan ◽  
Jinjie Wang ◽  
Heng Liu ◽  
...  

2018 ◽  
Vol 46 (8) ◽  
pp. 999-1001 ◽  
Author(s):  
Mary B. Nabity

Traditional biomarkers of renal disease have a number of limitations, whether evaluating veterinary patients or performing preclinical toxicity studies. Serum creatinine and urea nitrogen are affected by nonrenal influences that limit their usefulness for detecting small but significant decreases in glomerular filtration rate (GFR) in veterinary patients. These nonrenal influences can be more controlled in preclinical studies than in clinical patients; however, because of its high functional reserve, these estimates of GFR are insensitive for detecting kidney injury prior to loss of a substantial proportion of functioning nephrons. Urine biomarkers can be highly sensitive for tubular or glomerular injury that might lead to irreversible damage to the nephron. Several proteins are qualified by the Food and Drug Administration for nonclinical application as urinary biomarkers of drug-induced nephrotoxicity, and many of these also have preliminary data supporting their usefulness for kidney injury in dogs and cats. In addition to these relatively recently identified biomarkers, efforts are underway to discover new renal biomarkers using a variety of techniques including liquid chromatography–mass spectrometry and small RNA sequencing. Ultimately, the interplay between preclinical studies and clinical patients in discovery and validation of renal biomarkers is critical to their successful implementation.


2009 ◽  
Vol 133 (2) ◽  
pp. 268-278
Author(s):  
Lois J. Arend ◽  
Tibor Nadasdy

Abstract Context.—Many new therapies have emerged within the last 5 to 10 years to treat a variety of conditions. Several of these have direct or indirect renal toxicities that may go undiagnosed without careful attention of the pathologist to a patient's clinical history, particularly the addition of new medications or treatments. Objective.—To discuss patterns of renal injury resulting from medications or therapeutic regimens that have been introduced within the last 10 years. Recognition of these patterns may allow the pathologist to alert the attending clinician to a possible drug-induced renal injury and prevent further deterioration of renal function and possible chronic kidney disease. Data Sources.—A review of recent literature and unpublished observations of case-derived material. Conclusions.—A number of newer therapies have emerged as agents of renal toxicity, producing a variety of pathologic changes in the kidney. The outcome can be acute or chronic glomerular, tubular, interstitial, and/or vascular injury. Some drugs will result in irreversible changes and end-stage renal disease, whereas many of the alterations can be reversed with removal of the offending agent, avoiding potential long-term kidney injury.


1991 ◽  
Vol 90 (2) ◽  
pp. 241-248 ◽  
Author(s):  
Emanuel Farrugia ◽  
Timothy S. Larson
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document